EQUITA assisted ACS Dobfar

K Finance - Mid-market M&A advisory
ACS Dobfar
ACS Dobfar

ACS Dobfar, an Italian chemical-pharmaceutical group leader worldwide in the manufacturing of Active Pharmaceuticals Ingredients (APIs) and Final Dosage Forms (FDFs) in the antibiotic sector worldwide, received a Eur 175 million term loan financing through an underwriting deal closed with Unicredit and Natixis in Italy.

ACS Dobfar achieved a consolidated turnover of EUR 586 million in 2015.

K Finance (Clairfield Italy) assisted ACS Dobfar in the preparation and structuring of the deal and throughout the entire underwriting process. The legal advisor was Baker & McKenzie.

The transaction in a nutshell

2016 06 Tombstone ACS

ACS Dobfar achieved a consolidated turnover of EUR 586 million in 2015

Client:
ACS Dobfar
Date:
July 2016
Mandate:
ACS Dobfar received a 175 million term loan financing
Role:
Financial Advisor
Value:
Undisclosed
Typology:
M&A advisory
Advisor:
EQUITA Mid Cap Advisory

The company

ACS Dobfar (www.acsdobfar.it) is an Italian chemical-pharmaceutical company based in the province of Milan, Italy, at the head of a multinational group that is a leader in the production of active pharmaceutical ingredients (´API´) and so-called ´finished dosage forms´ (´FDF´) in the field of sterile injectable antibiotics. In 2015, it reported a consolidated turnover of Euro 586 million.